{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:38:57Z","timestamp":1782254337327,"version":"3.54.5"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0014_s_005_w2aab3b7b7b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>GATA-3 is a potential marker for detection of metastatic breast carcinoma, reportedly more sensitive than mammaglobin (MAM) and GCDFP-15. We aim to compare the sensitivity of GATA-3, MAM and GCDFP-15 in determining the breast origin of malignant effusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0014_s_006_w2aab3b7b7b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell blocks from 27 cases of serous effusions positive for metastatic breast cancer were retrieved. Immunohistochemistry for GATA-3, MAM, gross cystic disease fluid protein 15 (GCDFP-15), estrogen receptor (ER) and progesterone receptor (PR) was performed on cell-block micro-array. Statistical analysis using two ways Chi square, one-way ANOVA and multiple regression was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0014_s_007_w2aab3b7b7b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The detection rate of breast cancer in serous fluid was significantly higher with GATA-3 (88.8\u2006%, X2=15.9, p=0.00034) than with MAM (51.8\u2006%) and GCDFP-15 (37.0\u2006%). All ER positive cases (19) were GATA-3 positive. Conversely, all GATA-3 negative cases (3) were ER negative. The intensity of stain and percentage of positive cells were significantly higher with GATA-3 (p&lt;0.0001) than with MAM and GCDFP-15. The intensity and percentage of positive cells score of GATA-3 were statistically associated with ER stain intensity and percentage of positive cell scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0014_s_008_w2aab3b7b7b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GATA3 is a sensitive marker, superior to MAM and GCDFP-15 in determining the breast origin of metastatic adenocarcinoma. It is also strongly associated with ER expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0014","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T06:28:40Z","timestamp":1501136920000},"page":"143-148","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study"],"prefix":"10.1515","volume":"2","author":[{"given":"Mohamed I.","family":"El Hag","sequence":"first","affiliation":[{"name":"Department of Anatomic Pathology , University of Pittsburgh Medical Center , Pittsburgh , PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani M.","family":"Hag","sequence":"additional","affiliation":[{"name":"Mercy St. Elizabeth Hospital , Youngstown , OH , USA"},{"name":"Master of Science program in Clinical Research , Case Western Reserve University School of Medicine , Cleveland , OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer P.","family":"Ha","sequence":"additional","affiliation":[{"name":"Akron Children Hospital , Akron , OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire W.","family":"Michael","sequence":"additional","affiliation":[{"name":"Department of Pathology , University Hospitals Cleveland Medical Center\/Case Western Reserve University , MSPTH 5077, 11100 Euclid Ave Rm 212B , Cleveland , OH 44106 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"2025120909192904584_j_pp-2017-0014_ref_001_w2aab3b7b7b1b6b1ab2b1b1Aa","unstructured":"Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol 1993;13:4011\u201322."},{"key":"2025120909192904584_j_pp-2017-0014_ref_002_w2aab3b7b7b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Pai SY, Truitt ML, Ting CN, Leiden JM, Glimcher LH, Ho IC. Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 2003;19:863\u201375.","DOI":"10.1016\/S1074-7613(03)00328-5"},{"key":"2025120909192904584_j_pp-2017-0014_ref_003_w2aab3b7b7b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Asselin-Labat M-L, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007;9:201\u20139.","DOI":"10.1038\/ncb1530"},{"key":"2025120909192904584_j_pp-2017-0014_ref_004_w2aab3b7b7b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Asselin-Labat M-L, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor Caspase-14. Mol Cell Biol 2011;31:4609\u201322.","DOI":"10.1128\/MCB.05766-11"},{"key":"2025120909192904584_j_pp-2017-0014_ref_005_w2aab3b7b7b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014;38:13\u201322.","DOI":"10.1097\/PAS.0b013e3182a0218f"},{"key":"2025120909192904584_j_pp-2017-0014_ref_006_w2aab3b7b7b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Hum Pathol 2016;47:26\u201331.","DOI":"10.1016\/j.humpath.2015.09.015"},{"key":"2025120909192904584_j_pp-2017-0014_ref_007_w2aab3b7b7b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer 2010;1:1178\u201388.","DOI":"10.1177\/1947601911404223"},{"key":"2025120909192904584_j_pp-2017-0014_ref_008_w2aab3b7b7b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol 2014;142:64\u201371.","DOI":"10.1309\/AJCP8H2VBDSCIOBF"},{"key":"2025120909192904584_j_pp-2017-0014_ref_009_w2aab3b7b7b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"El Hag MI, Ha J, Farag R, El Hag AM, Michael CW. Utility of GATA-3 in the work-up of breast adenocarcinoma and its differential diagnosis in serous effusions. Diagn Cytopathol 2016;44:731\u20136.","DOI":"10.1002\/dc.23521"},{"key":"2025120909192904584_j_pp-2017-0014_ref_010_w2aab3b7b7b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Krings G, Nystrom M, Mehdi I, Vohra P, Chen YY. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum Pathol 2014;45:2225\u201332.","DOI":"10.1016\/j.humpath.2014.06.022"},{"key":"2025120909192904584_j_pp-2017-0014_ref_011_w2aab3b7b7b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008;17:365\u201373.","DOI":"10.1158\/1055-9965.EPI-06-1090"},{"key":"2025120909192904584_j_pp-2017-0014_ref_012_w2aab3b7b7b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, et al. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 2015;67:245\u201354.","DOI":"10.1111\/his.12645"},{"key":"2025120909192904584_j_pp-2017-0014_ref_013_w2aab3b7b7b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999;84:122\u20138.","DOI":"10.1002\/(SICI)1097-0215(19990420)84:2<122::AID-IJC5>3.0.CO;2-S"},{"key":"2025120909192904584_j_pp-2017-0014_ref_014_w2aab3b7b7b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor ?? expression in breast cancer. Cancer Res 2007;67:6477\u201383.","DOI":"10.1158\/0008-5472.CAN-07-0746"},{"key":"2025120909192904584_j_pp-2017-0014_ref_015_w2aab3b7b7b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Fatima N, Osunkoya AO. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder. Hum Pathol 2014;45:1625\u20139.","DOI":"10.1016\/j.humpath.2014.03.015"},{"key":"2025120909192904584_j_pp-2017-0014_ref_016_w2aab3b7b7b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Shield PW, Papadimos DJ, Walsh MD. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol 2014;122:307\u201312.","DOI":"10.1002\/cncy.21393"},{"key":"2025120909192904584_j_pp-2017-0014_ref_017_w2aab3b7b7b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Braxton DR, Cohen C, Siddiqui MT. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens. Diagn Cytopathol 2015;43:271\u20137.","DOI":"10.1002\/dc.23206"},{"key":"2025120909192904584_j_pp-2017-0014_ref_018_w2aab3b7b7b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Lew M, Pang JC, Jing X, Fields KL, Roh MH. Young investigator challenge: the utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Cancer Cytopathol 2015;123:576\u201381.","DOI":"10.1002\/cncy.21574"},{"key":"2025120909192904584_j_pp-2017-0014_ref_019_w2aab3b7b7b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Wendroth SM, Mentrikoski MJ, Wick MR. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Ann Diagn Pathol 2015;19:6\u20139.","DOI":"10.1016\/j.anndiagpath.2014.12.001"},{"key":"2025120909192904584_j_pp-2017-0014_ref_020_w2aab3b7b7b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Liu H, Shi J, Prichard JW, Gong Y, Lin F. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Am J Clin Pathol 2014;141:648\u201355.","DOI":"10.1309\/AJCP0Q9UQTEESLHN"},{"key":"2025120909192904584_j_pp-2017-0014_ref_021_w2aab3b7b7b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Pu RT, Giordano TJ, Michael CW. Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. Cancer 2008;114:300\u20136.","DOI":"10.1002\/cncr.23797"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/3\/article-p143.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0014\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:55:19Z","timestamp":1765274119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0014\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,8,31]]}},"alternative-id":["10.1515\/pp-2017-0014"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0014","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,17]]}}}